THE COST-EFFECTIVENESS OF LOW-MOLECULAR-WEIGHT HEPARIN VS UNFRACTIONATED HEPARIN IN GENERAL AND ORTHOPAEDIC SURGERY: AN ANALYSIS FOR THE GERMAN HEALTHCARE SYSTEM
- 31 July 1999
- journal article
- Published by Elsevier in Pharmacological Research
- Vol. 40 (1) , 83-89
- https://doi.org/10.1006/phrs.1999.0479
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- A pharmacoeconomic assessment of enoxaparin and warfarin as prophylaxis for deep vein thrombosis in patients undergoing knee replacement surgeryClinical Therapeutics, 1998
- THE PERSPECTIVE OF A PHARMACOECONOMIC STUDY: TARGETING FOR AUDIENCESPharmacological Research, 1997
- Subcutaneous Low-Molecular-Weight Heparin vs Warfarin for Prophylaxis of Deep Vein Thrombosis After Hip or Knee ImplantationArchives of internal medicine (1960), 1997
- Cost-effectiveness of the low molecular weight heparin reviparin sodium in thromb oprophylaxisThrombosis Research, 1996
- Comparison of the cost of preventing postoperative deep vein thrombosis with either unfractionated or low molecular weight heparinBritish Journal of Surgery, 1996
- Economic evaluation of standard heparin and enoxaparin for prophylaxis against deep vein thrombosis in elective hip surgeryBritish Journal of Surgery, 1994
- Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysisThe Lancet, 1992
- Current status of pulmonary thromboembolic disease: Pathophysiology, diagnosis, prevention, and treatmentAmerican Heart Journal, 1982
- Cost Effectiveness of Clinical Diagnosis, Venography, and Noninvasive Testing in Patients with Symptomatic Deep-Vein ThrombosisNew England Journal of Medicine, 1981
- Prophylaxis of Venous ThromboembolismAnnals of Surgery, 1980